Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Kevin Raymond

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Cancer|March 7, 2006
Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylateDejka M Steinert, Mauricio Oyarzo, Xuemei Wang, et al.
Journal of Pediatric Surgery|January 18, 2006
Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcomaMatthew T Harting, Martin L Blakely, Norman Jaffe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylateJohn C McAuliffe, Alexander J F Lazar, Dan Yang, et al.
Skeletal Radiology|September 18, 2009
Tumor necrosis in osteosarcoma: inclusion of the point of greatest metabolic activity from F-18 FDG PET/CT in the histopathologic analysisColleen M Costelloe, A Kevin Raymond, Nancy E Fitzgerald, et al.
Cancer|June 29, 2004
A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosisShreyaskumar R Patel, Nicholas Papadopolous, A Kevin Raymond, et al.
Plastic and Reconstructive Surgery|January 1, 2009
Use of vascularized periosteum or bone to improve healing of segmental allografts after tumor resection: an ovine rib modelDavid W Chang, William C Satterfield, Daegu Son, et al.
Journal of Vascular and Interventional Radiology : JVIR|November 5, 2004
Percutaneous ultrasound-guided biopsy in the definitive diagnosis of osteosarcomaKamran Ahrar, Judy U Himmerich, Cynthia E Herzog, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 5, 2009
18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcomaColleen M Costelloe, Homer A Macapinlac, John E Madewell, et al.
American Journal of Surgery|December 16, 2003
Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?Courtney L Scaife, Kelly K Hunt, Shreyaskumar R Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Cancer|March 7, 2006
Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylateDejka M Steinert, Mauricio Oyarzo, Xuemei Wang, et al.
Journal of Pediatric Surgery|January 18, 2006
Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcomaMatthew T Harting, Martin L Blakely, Norman Jaffe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2007
Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylateJohn C McAuliffe, Alexander J F Lazar, Dan Yang, et al.
Skeletal Radiology|September 18, 2009
Tumor necrosis in osteosarcoma: inclusion of the point of greatest metabolic activity from F-18 FDG PET/CT in the histopathologic analysisColleen M Costelloe, A Kevin Raymond, Nancy E Fitzgerald, et al.
Cancer|June 29, 2004
A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosisShreyaskumar R Patel, Nicholas Papadopolous, A Kevin Raymond, et al.
Plastic and Reconstructive Surgery|January 1, 2009
Use of vascularized periosteum or bone to improve healing of segmental allografts after tumor resection: an ovine rib modelDavid W Chang, William C Satterfield, Daegu Son, et al.
Journal of Vascular and Interventional Radiology : JVIR|November 5, 2004
Percutaneous ultrasound-guided biopsy in the definitive diagnosis of osteosarcomaKamran Ahrar, Judy U Himmerich, Cynthia E Herzog, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 5, 2009
18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcomaColleen M Costelloe, Homer A Macapinlac, John E Madewell, et al.
American Journal of Surgery|December 16, 2003
Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?Courtney L Scaife, Kelly K Hunt, Shreyaskumar R Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke, Cathryn Rankin, George D Demetri, et al.
Pageof 3